Super Investors Bet on Neuland Labs

India's top investors are turning to niche healthcare plays like Neuland Laboratories, a key API maker for oncology and other therapies. This shift mirrors pivots to IVF and cancer care stocks, driven by booming demand. Investor Pivot Super investors like Vijay Kedia and Mukul Agrawal hold big stakes in Neuland Labs, with holdings worth hundreds of crores as of March 2026. Their move signals faith in the company's growth in complex APIs for anti-cancer drugs and peptides. Institutional ownership has risen, with DIIs at 15.84% and FIIs at 20.46%. Company Strengths Neuland Labs makes APIs for oncology, CNS, and cardiovascular uses, serving global markets. Revenue hit Rs 1,575 Cr in FY26, with profit at Rs 179 Cr and 66.9% CAGR over five years. Q2 FY26 PAT jumped 195% YoY to Rs 97 Cr, fueled by CDMO projects. Shareholder Benefits This investor interest boosts Neuland's stock, up over 40% in a year to Rs 17,000 levels, creating wealth for holders. Strong demand for niche APIs ensures steady orders, high margins (EBITDA 26-28%), and ROCE of 18.7%. It validates the business model, drawing more capital for expansion. Potential Risks High valuations (P/E 86-115, P/B 12-13.5) mean the stock trades at a premium, risking corrections if growth slows. Promoter holding dipped slightly over three years. Reliance on CDMO cycles could hurt if biotech funding dips. Overall Value For shareholders, super investor backing is highly beneficial, signaling long-term upside in India's healthcare boom. It enhances liquidity and visibility, outweighing risks for patient holders. Stock outperformed pharma peers, with 64% gains in a year.